Article Versions Notes

Wu Z-X, Yang Y, Teng Q-X, Wang J-Q, Lei Z-N, Wang J-Q, Lusvarghi S, Ambudkar SV, Yang D-H, Chen Z-S. Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers. 2020; 12(1):186. https://doi.org/10.3390/cancers12010186

Wu, Zhuo-Xun, Yuqi Yang, Qiu-Xu Teng, Jing-Quan Wang, Zi-Ning Lei, Jing-Qiu Wang, Sabrina Lusvarghi, Suresh V. Ambudkar, Dong-Hua Yang, and Zhe-Sheng Chen. 2020. "Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance" Cancers 12, no. 1: 186. https://doi.org/10.3390/cancers12010186

Wu, Z.-X., Yang, Y., Teng, Q.-X., Wang, J.-Q., Lei, Z.-N., Wang, J.-Q., Lusvarghi, S., Ambudkar, S. V., Yang, D.-H., & Chen, Z.-S. (2020). Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers, 12(1), 186. https://doi.org/10.3390/cancers12010186